Good morning from the Financial Times. Today is Monday, August 24th. And this is your F.T. news briefing.

Donald Trump considers fast tracking a coronavirus vaccine before November's US presidential election.

And global dividends are getting hit hard this year because of the pandemic.

Plus a look at the hedge fund at the heart of Neiman Marcus's bankruptcy battle.

I'm Mark Filipino and here's the news you need to start your day.

It is a key week for Donald Trump as the Republican National Convention kicks off today.

And the Trump administration wants to show that it's got the coronavirus under control

ahead of the US presidential election.

The F.T. reported yesterday that the White House is considering bypassing normal US regulatory

standards to fast track an experimental coronavirus vaccine from the UK.

The idea is to give Americans access to it before the election this autumn.

The F.T. David Crow explains the political ramifications behind a move like this one.

One of the plans that's under consideration is to go for a vaccine that's been developed in the UK

in a partnership between AstraZeneca, the UK-based drugmaker and Oxford University.

And they've zeroed in on a study of 10,000 volunteers in the UK, and they're hoping that that produces successful results that would allow them to give the vaccine what's known as emergency use approval. The problem with this is that all of the US scientific

agencies have said that a study of 30,000, so much bigger than 10,000 would be needed before a vaccine could be used in the US.

Now, David, the timing of this can't be coincidental, right?

How is Trump using this as part of his campaign?

Yeah, so I mean the Trump administration's response to the coronavirus has been widely

criticized. But one area where you know they have had some success is in vaccine

development even if a vaccine isn't approved in time for the election, simply

the speed with which they have identified candidates and enrolled trials

...